300653SZSE

2025 Annual Social Responsibility Report

✨ AI Summary

This report reflects Yantai Zhenghai Bio-Technology Co., Ltd.'s commitment to social responsibility in 2025, covering stakeholders such as shareholders, employees, and the environment. Key figures include a planned cash dividend of approximately 60.36% of net profit. The company aims to enhance its governance structure and maintain compliance while fostering sustainable development and innovation in regenerative medicine.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Preface

This report objectively reflects the company's active fulfillment of social responsibility in its production and management activities, serving as an important manifestation of the company's social responsibility towards shareholders, creditors, employees, suppliers, customers, and the ecosystem in 2025.

  1. Report Scope
    Yantai Zhenghai Bio-Technology Co., Ltd. and its wholly-owned subsidiaries.

  2. Report Time Frame
    From January 1, 2025, to December 31, 2025. Some content may extend beyond this period to comply with the principles of completeness and continuity in information disclosure.

  3. Data Explanation
    The financial data disclosed in this report may differ from the company's 2025 annual report; in such cases, the 2025 annual report shall prevail. Other data is sourced from internal statistics.

  4. Terminology
    For ease of expression and reading, "Yantai Zhenghai Bio-Technology Co., Ltd." is referred to as "the company" in this report.

  5. Report Preparation Basis
    This report is prepared in accordance with the Company Law, the Shenzhen Stock Exchange's Self-Regulatory Guidelines for Listed Companies No. 2 - Normative Operations of Growth Enterprise Market Listed Companies, and in consideration of the company's actual situation.

  6. Contact Information
    Yantai Zhenghai Bio-Technology Co., Ltd.
    Board Office Address: No. 7 Nanjing Street, Yantai Economic and Technological Development Zone, Shandong Province
    Phone: 0535-6931997
    Fax: 0535-6931997
    Email: ir@zhbio.com

We hope this report serves as a bridge for communication between the company and all sectors of society, providing a window for investors, employees, and the public to understand and recognize the company, and to play a role in social supervision, enabling the company to perform better in terms of social responsibility. We welcome feedback and constructive suggestions from all sectors of society.

Table of Contents

  • Preface .................................................................................................................. 2
  • Section 1 Company Overview .............................................................................. 4
  • Section 2 Protection of Shareholders and Creditors' Rights ............................... 6
  • Section 3 Protection of Employees' Rights .......................................................... 11
  • Section 4 Protection of Suppliers and Customers' Rights .................................. 14
  • Section 5 Environmental Protection and Sustainable Development .................... 15
  • Section 6 Public Relations and Social Welfare .................................................... 18
  • Section 7 Outlook on Social Responsibility ....................................................... 22

Section 1 Company Overview

1. Company Profile

Yantai Zhenghai Bio-Technology Co., Ltd. was established in 2003 and successfully listed on May 16, 2017 (stock code: 300653). It is a key national research and development unit, a participant in the national "863" program, and a high-tech enterprise. The company is dedicated to the research, production, and sales of biological regenerative materials and is one of the earliest companies in China to focus on Class III implantable medical devices in the regenerative medicine sector.

Currently, the company's listed products include oral repair membranes, meninges series products, active biological bone, calcium silicate bioceramic oral bone repair materials, and skin repair membranes, which are widely used in various fields such as oral and maxillofacial surgery, neurosurgery, orthopedics, and trauma surgery. The company's brand "Hai Ao" has accumulated service for millions of patients over more than a decade of academic accumulation and market promotion, covering over 10,000 public and private institutions, earning praise and recognition from numerous clinical doctors and professional clients.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.